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A confusion in antibody
identification: anti-D production
after anti-hrB
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It is well known that certain combinations of alloantibodies are
frequently found together. Patients with sickle cell disease (SCD) are
mostly ofAfrican ancestry,and they may make anti-hrB. A transfusion
of hrB– blood is often achieved by using e– (R2R2) RBCs;it is generally
believed that hrB– patients readily make anti-E or a“broad-spectrum”
anti-Rh34 (-HrB). We describe two multiply transfused D+ patients
with SCD and a history of anti-hrB who subsequently produced anti-
D. This raises the question whether anti-hrB together with anti-D is
a more common antibody combination than anti-hrB with anti-E or
anti-Rh34. Immunohematology 2007;23:158–60.
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It is well known by immunohematologists that
certain combinations of alloantibodies are frequently
found together, for example, anti-C with anti-e; anti-E
with anti-c;and anti-Lea with anti-Leb. Patients ofAfrican
ancestry with sickle cell disease (SCD) often require
chronic transfusion therapy, and they may have variant
antigens that make them prone to produce unusual
antibody combinations. For example, patients with
variant RHCE genes may make alloanti-e-like antibodies,
including anti-hrB. After anti-hrB has been identified,
transfusion of hrB– blood is often achieved by using e–
(R2R2) RBC components because haplotypes that lack e
are hrB–, and such blood is more readily available than
e+, hrB– blood.1 However, it is generally believed that
these patients readily make anti-E with or without a
“broad-spectrum” anti-Rh34 (-HrB).2,3 If such patients
receive frequent transfusions, additional antibodies are
likely to be formed,making antibody identification and
finding compatible blood complicated. We describe
here two multiply transfused D+ patients with SCD and
a history of anti-hrB (plus other alloantibodies) who
subsequently made anti-D.As certain D variant haplo-
types are often associated with hrB– haplotypes,4,5 this
raises the question as to whether anti-hrB together with
anti-D, in D+ patients, is a more common combination
than anti-hrB with anti-E or anti-Rh34.
Case Reports
Patient 1
AnAfricanAmerican woman with clinical sepsis and
a history of SCD β-thalassemia was admitted for the
surgical removal or drainage of a left subphrenic abscess.
Although her baseline Hct level was normally 30% to
36%, her admission Hct was 18.9%. Before admission,
she was known to be D+ and to have anti-hrB, -E, -M,and
a warm autoantibody. A sample was submitted to the
American Red Cross Northern Ohio Region Reference
Laboratory. It was determined that the patient’s serum
contained the previously identified anti-hrB and anti-E;
however, the previously detected anti-M and warm
autoantibody were no longer detectable. Attempts were
made to obtain compatible blood,including the procure-
ment of D–– units. Because of the urgency to proceed
with surgery and the unavailability of hrB– units, least
incompatible blood was selected to support this patient
in the perioperative period. She received two units of
crossmatch compatible and four units of crossmatch
incompatible blood on the day after her admission.
During the following 12 days, her Hct stabilized at 30%
to 35%. Surgery was delayed because the patient was
clinically stable on broad-spectrum antibiotic therapy.
On the 13th day after transfusion,her Hct precipitously
fell to 20%. During the next 5 days, despite transfusion
of six least incompatible units, including one that was
E–, hrB–, her Hct further declined to 13%. Her
reticulocyte count diminished to essentially zero, and a
bone marrow aspiration performed at this time
demonstrated pure RBC aplasia. When D+,hrB–,and D––
RBC components were subsequently obtained, they
were strongly incompatible with the patient’s posttrans-
fusion serum,thereby ruling out the possibility of anti-E
and anti-Rh34 as the sole additional specificities. Repeat
testing of her posttransfusion serum revealed 4+
reactivity with the antibody screening RBCs. The
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patient’s RBCs were positive in the DAT with anti-IgG. A
sample was investigated for the possible development
of an additional antibody to a high-prevalence antigen.
In a selected RBC panel, Rhnull; D–, hrB–; and some D+,
hrB– RBCs that lacked the other relevant antigens were
compatible. Because DIIIa RBCs are frequently hrB–
(andVS+),1 patients who make anti-hrB are likely to have
the DIIIa phenotype and be at risk of making anti-D.
Thus,we considered the possibility that the patient had
made anti-D. The compatible D+,hrB– RBCs were either
D–, or were determined by DAK typing (they were
DAK+)6 and by DNA (prepared from WBCs) analysis
using PCR-RFLP as described6,7 to have the partial D
phenotype, DIIIa. Anti-D made by a DIIIa person does
not react with DIIIa RBCs and explains the compatibility
of some D+,hrB– RBCs. Transfusion was withheld from
the patient for 1 week, during which time her Hct
remained less than 15%. An episode of chest pain
prompted the transfusion of a D–, E–, hrB– compatible
RBC component slowly in two aliquots. After this
transfusion her Hct stabilized at 20%. During the next 3
weeks her reticulocyte count increased to 10%,and she
achieved a Hct of 30% with no further transfusion
therapy.
Patient 2
AnAfricanAmerican man with SCD was admitted to
the hospital with low hemoglobin and hematocrit levels
and a painful sickle cell crisis. His serum was known to
contain anti-hrB, -C, -E, and -K. He had received trans-
fusions on multiple occasions before his serum strongly
agglutinated some RBCs lacking these antigens.
Attempts to locate compatible blood were unsuccessful.
When tested with a panel of hrB– RBC samples that
lacked C, E, and K, his serum did not agglutinate eight
samples (one of these samples was E+) and did
agglutinate four samples (two of which were E+). One
of the eight nonreactive samples was D–. It was shown
that the compatible D+ samples and the patient’s RBCs
were DIIIa. With the experience that had been gained
from Patient 1, anti-D was quickly identified in this
patient’s serum.
Discussion
Given the reputed immunogenicity of D,it surprised
us that these patients produced anti-D after anti-hrB and
other alloantibodies. One explanation for this unexpect-
ed result is that the patients with a partial D on their
RBCs produce an anti-D to a part, but not all, of D. In
both cases presented here,many transfusions of D+,hrB–
RBCs (including R2R2) were tolerated before anti-D was
produced. The partial D phenotype, DIIIa, which may
be present in approximately 4 percent of Americans
with African ancestry,6 is not readily identified because
DIIIa RBCs are strongly agglutinated by reagent and
single-clone monoclonal anti-D. The presence of anti-D
may not be readily apparent when a panel of D+, hrB–
RBCs is tested because some, but not all, may be DIIIa.
DNA analysis has shown that altered RHCE genes are
often in cis with genes encoding partial D pheno-
types.4,5 Thus, patients whose RBCs possess a partial D
phenotype with a partial e phenotype can type positive
for these antigens and have an alloantibody apparently
of the same specificity, that is D+ with alloanti-D,and e+
with alloanti-e. This can dramatically complicate anti-
body identification, as well as our ability to provide
compatible blood components to such patients. It is
important to remember that providing compatible
blood components for patients with anti-e-like anti-
bodies can be confounded by the presence of anti-D,
and that a panel of RBCs lacking a high-prevalence e-
variant antigen (such as hrB) is likely to include some
RBCs with a partial D phenotype. Thus, the pattern of
reactivity will not be that expected for anti-D. In these
patients, reactivity with R2R2 RBCs may be attributable
to anti-D and not anti-E or anti-Rh34. We have since
tested other patients whose serum first contained anti-
e-like antibodies and then anti-D, which shows that in
certain patients this phenomenon is not especially rare.
When testing serum from patients of African ancestry,
think anti-D!
Providing blood for transfusion to patients with
complex serologic problems has always been
challenging; however, providing blood for the patients
described in this paper is particularly difficult. They
require unique antigen combinations that are found only
in donors ofAfrican descent. A nationwide search in the
United States for blood for Patient 2 failed to identify any
compatible donors. Hemoglobin substitutes might be
useful in these cases, but they are rarely available for
compassionate use, and none is currently approved by
the U.S.Food and DrugAdministration. Because the only
reagent RBCs that were serologically compatible with
the patient had been received on a RBC exchange from
South Africa, the blood center in Durban, South Africa,
was contacted. They generously provided two units of
blood from one of the compatible donors; however,
there is an ongoing concern that such blood should not
be used because the blood center in South Africa had
not performed nucleic acid testing for viral markers.
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The practice of prophylactically matching patients
with SCD for Rh and K is widespread; however, such
matching would not prevent this infrequent type of
alloimmunization. Patients, as described in these case
studies,who have partial Rh antigens will likely type D+,
even though they are at risk of being sensitized to anti-
D. Because the Rh phenotype that is compatible with
these patients can only be found in donors of African
ancestry, an ongoing effort to recruit, type, and retain
these minority donors must become a priority in the
nation’s blood centers.
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